Spontaneous resolution of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

Published

Journal Article

Secondary hemophagocytic lymphohistiocytosis (sHLH) is a reactive, proliferative disorder of the immune system resulting in lymphohistiocytic proliferation, hemophagocytosis, and cytokine dysregulation. The most common infectious trigger in sHLH is Epstein-Barr virus (EBV-HLH). Current treatment protocols for EBV-HLH have a cure rate of approximately 75%; however, there are significant toxicities associated with these therapies. We present two patients with EBV-HLH who experienced spontaneous resolution of their disease prior to the initiation of therapy, suggesting there may be a subgroup of patients with EBV-HLH who do well with conservative management and can avoid potentially toxic therapies.

Full Text

Duke Authors

Cited Authors

  • Belyea, B; Hinson, A; Moran, C; Hwang, E; Heath, J; Barfield, R

Published Date

  • October 2010

Published In

Volume / Issue

  • 55 / 4

Start / End Page

  • 754 - 756

PubMed ID

  • 20806367

Pubmed Central ID

  • 20806367

Electronic International Standard Serial Number (EISSN)

  • 1545-5017

Digital Object Identifier (DOI)

  • 10.1002/pbc.22618

Language

  • eng

Conference Location

  • United States